Kura Oncology (KURA) announced receipt of a $30M milestone payment under its collaboration agreement with Kyowa Kirin in connection with the dosing of the first patient in the second of two KOMET-017 Phase 3 registrational trials of ziftomenib, a once-daily, investigational oral menin inhibitor. Kura previously announced receipt of the first $30M milestone triggered by patient dosing in the KOMET-017 trials in October. Kura has received a total of $105M in milestone payments to date and expects to receive up to $315M in additional, near-term milestones under the collaboration.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KURA:
- Kura Oncology (KURA) Q3 Earnings Cheat Sheet
- Kura Oncology’s Promising AML Study: A Potential Game Changer?
- Kura Oncology’s Promising Phase 1 Study on AML Treatment: Key Insights for Investors
- Kura Oncology’s KO-2806 Study: A New Hope for Advanced Solid Tumors?
- Kura Oncology’s Promising GIST Trial: A Potential Game-Changer in Cancer Treatment